Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the sequencing and design of complex sugars for the development of improved versions of existing drugs. The company also engages in the development of novel drugs and the discovery of new biological processes. Its products include M-Enoxaparin, a technology-enabled generic version of Lovenox, which is used to prevent and treat deep vein thrombosis and acute coronary syndrome (ACS); M-Dalteparin, a technology-enabled generic version of LMWH Fragmin; and M118 an LMWH designed to provide flexible administration as baseline therapy for patients with ACS. It has collaborations with Sandoz to develop and commercialize injectable...